Evidence map›Paper›PMID 41699622›Full record

ReviewRespiratory research2026

GLP-1RAs: antidiabetic drug crossover-new hope for chronic inflammatory airway diseases.

Yinan Chen, Yili Shen, Hui Shen, Zhicong Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yinan ChenDepartment of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Yili ShenDepartment of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China. shenxisa@126.com.
Hui ShenDepartment of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China. 37696833@qq.com.
Zhicong LiuDepartment of Respiratory Medicine, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China. liuzhicongcong@163.com.

Funding

Yili Shen 2023GY15;
6 · The paper itself

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent a novel class of antidiabetic agents recognized not only for their efficacy in glycemic control and weight management but also for their distinctive cardiovascular benefits. Type 2 diabetes mellitus, a prevalent chronic metabolic disorder worldwide, frequently coexists with chronic inflammatory airway diseases (CIADs), including chronic obstructive pulmonary disease (COPD), asthma, and obstructive sleep apnea (OSA). In recent years, growing attention has been directed toward the potential role of GLP-1RAs in the context of CIADs. This review examines the mechanistic underpinnings of GLP-1RAs in CIADs and evaluates their therapeutic potential in COPD, asthma, and OSA. Clinical evidence indicates that GLP-1RAs can reduce the risk of acute exacerbations in COPD, attenuate obesity-associated asthma exacerbations, and improve respiratory outcomes in patients with OSA. Although certain findings remain inconsistent and prospective clinical studies are still limited, the therapeutic promise of GLP-1RAs in CIADs has been preliminarily supported. Further large-scale randomized controlled trials are warranted to clarify their precise effects in chronic inflammatory airway diseases and to assess long-term efficacy and safety.

Indexed as

AsthmaDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsPulmonary Disease, Chronic ObstructiveSleep Apnea, ObstructiveAnimalsHumansGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsAsthmaChronic inflammatory airway diseasesChronic obstructive pulmonary diseaseGlucagon-like peptide receptor agonistsMechanism of actionObstructive sleep apnea

Identifiers

PMID41699622
PMCPMC13014972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.